Vision
Quant Biomarkers AG envisions a future in which chronic pathology is detected years before irreversible damage occurs, enabling earlier prevention and intervention across the cardio-kidney-metabolic (CKM) disease spectrum.
Grounded in unique, validated biology, we provide a solution that connects these systems through early, actionable signals—RenoRisk™.
By shifting kidney care from late-stage intervention to early, proactive risk detection, we aim to improve outcomes for patients, clinicians, healthcare systems, and drug developers worldwide.
Mission
To deliver clinically actionable biomarkers that detect kidney injury early and guide better treatment decisions.
Our mission is to advance next-generation kidney diagnostics that:
- Detect CKD 3–6 years earlier than current standards
- Identify fast progressors before therapeutic windows close
- Enable real-time monitoring
- Support drug development through validated surrogate endpoints
Through scientific rigor and translational focus, we bridge clinical care and pharma innovation within the cardio-kidney-metabolic (CKM) disease spectrum.
Partners
Quant Biomarkers Secures Approval for HKD 6 Million Funding under Hong Kong’s HSITP IGNITE Programme
